

## Differential Effects of Methoxylated *p*-Coumaric Acids on Melanoma in B16/F10 Cells

Hoon Seok Yoon<sup>1</sup>, Nam-Ho Lee<sup>1,2</sup>, Chang-Gu Hyun<sup>1,2</sup>, and Dong-Bum Shin<sup>3</sup>

<sup>1</sup>Cosmetic Sciences Center, <sup>2</sup>Faculty of Chemistry and Cosmetics, and <sup>3</sup>Department of Food Science and Nutrition, Jeju National University, Jeju 690-756, Korea

**ABSTRACT:** As an approach to search for chemopreventive agents, we tested *p*-coumaric acid, 3-methoxy-*p*-coumaric acid (ferulic acid), and 3,5-dimethoxy-*p*-coumaric acid (sinapic acid) in B16/F10 melanoma cells. Intracellular melanin contents were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and cytotoxicity of the compounds were examined by lactate dehydrogenase (LDH) release. *p*-Coumaric acid showed inhibitory effect on melanogenesis, but ferulic acid increased melanin content, and sinapic acid had almost no effect on melanogenesis. Treatment with ferulic acid resulted in a 2 to 3 fold elevation in the production of melanin. Correlatively, cell viability decreased in a dose-dependent manner when treated with ferulic acid. However, ferulic acid did not affect the LDH release from the cells. Treatment with sinapic acid resulted in a 50~60% elevation in the release of LDH when treated with a 200 µg/mL concentration and showed neither cytostasis nor increase of melanin synthesis in a dose-dependent manner. Taken together, *p*-coumaric acid inhibits melanogenesis, ferulic acid induces melanogenesis, and sinapic acid exerts cytotoxic effects in B16/F10 murine melanoma cells. The results indicate that the addition of methoxy groups to *p*-coumaric acid shows the melanogenic or cytotoxic effects in melanoma cells compared to the original compound. Therefore, this study suggests the possibility that methoxylated *p*-coumaric acid, ferulic acid can be used as a chemopreventive agent.

**Keywords:** methoxy groups, ferulic acid, sinapic acid, cytostasis, cytotoxicity

### INTRODUCTION

Melanoma, a type of cancer which forms from melanocytes, is the most lethal skin cancer in humans and its incidence and mortality rate has increased over the last three decades (1). A possibly less toxic approach for treating cancer involves reprogramming tumor cells to encounter irreversible growth arrest and terminal differentiation, referred to as differentiation therapy. In this scheme, neoplastic cells displaying atypical patterns of differentiation upon treatment with an appropriate agent lose proliferative capacity and terminally differentiate. The limitations of current cancer therapies underscore the need to develop less toxic and probably more specific and effective forms of treatment (2). Previous studies on melanoma-cell differentiation have reported that interferon (IFN) and melanocyte stimulating hormone (MSH) induce differentiation in melanocytes and melanoma cells (3,4).

Melanin plays a protective role in the linkage and symbiosis between melanocyte and keratinocyte as an anti-

oxidant. Melanogenesis indicates a marker of differentiation in human and murine melanoma cells. The process of melanoma cell differentiation includes melanin synthesis, the transport of melanin and anti-proliferation (5).

Methoxylated flavones with hydroxyl groups capped by methylation are shown to exert biologically and pharmacologically activities in the regulation of melanogenesis, differentiation, and other physiological conditions. Previous studies have been reported that methoxyflavones enhance metabolic stability and membrane transport in the intestine/liver, which results in the improvement of oral bioavailability (6). Nobiletin, a 5,6,7,8,3',4'-hexamethoxyflavone, triggers melanogenesis and differentiation in B16/F10 melanoma cells and induces neuritogenesis in PC12D cells (2,7,8). Sinensetin, a 5,6,7,3',4'-pentamethoxyflavone, has antiangiogenic effect in zebrafish and inhibited carrageenan-induced paw inflammation in mice (9,10). Tangeretin, a 5,6,7,8,4'-pentamethoxyflavone, inhibits a number of cellular activities such as growth of mammary cancer cells *in vitro* and cytolysis by

Received 18 November 2014; Accepted 29 December 2014; Published online 31 March 2015

Correspondence to Dong-Bum Shin, Tel: +82-64-754-3556, E-mail: shindb@jejunu.ac.kr

Copyright © 2015 by The Korean Society of Food Science and Nutrition. All rights Reserved.

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

natural killer (NK) cells *in vivo* (11).

Recently, studies have shown that melanogenesis is induced by methoxylated compounds, such as nobiletin, tangeretin, sinensetin, 4'-O-methylfisetin, scopletin (7-hydroxy-6-methoxycoumarin), 7-methoxycoumarin, scoparone (6,7-dimethoxycoumarin), and citropten (5,7-dimethoxycoumarin) (7,12-14), and stimulated by hydroxylated compounds, such as quercetin, naringenin, and isoliquiritigenin (15-17), while inhibited by diosgenin,  $\alpha$ -tocopheryl ferulate, and 2,5-dimethyl-4-hydroxy-3(2H)-furanone (18-20).

In this study, we report the chemopreventive effects of ferulic acid and sinapic acid in murine B16/F10 melanoma cells. By determining the intracellular melanin contents and cytostasis of the compounds *in vitro*, the stimulatory effects of the addition of methoxy groups to *p*-coumaric acid on melanogenesis and cytostasis were shown. This study presents the fundamental information on methoxy *p*-coumaric acids as a chemopreventive agent for melanoma.

## MATERIALS AND METHODS

### Materials

All solvents used were of analytical grade without any further purification.  $\alpha$ -Melanocyte stimulating hormone ( $\alpha$ -MSH), *p*-coumaric acid, ferulic acid, sinapic acid, and doxorubicin were purchased from Sigma Chemical Co. (St. Louis, MO, USA).

### Cell culture

B16/F10 murine melanoma cells were maintained in DMEM (Gibco BRL, Rockville, MD, USA) supplemented with 10% FBS (Gibco BRL), and 1% penicillin-streptomycin (10,000 U/mL and 10,000  $\mu$ g/mL, Gibco BRL). The cells were maintained in a humid atmosphere of 5% CO<sub>2</sub> at 37°C.

### Intracellular melanin contents

B16/F10 murine melanoma cells were seeded into 6-well plates at a density of  $1 \times 10^5$  cells per well. The cells were then treated with or without the test compounds at 37°C for 2 days. Next, the cells were washed with  $1 \times$  PBS and then collected in  $1 \times$  trypsin-EDTA, after which they were lysed with 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and 1% Triton X-100 in 67 mM sodium phosphate buffer (pH 6.8). The samples were then sonicated and centrifuged at 15,000 rpm for 15 min at 4°C. To extract the melanin from the pellets, 1 N sodium hydroxide (NaOH) was added to the pellets and subsequently incubated at 70°C for 4 h. The absorbance was then measured at 405 nm and the corresponding total protein was used to normalize the absorbance.

### Cell viability

The cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Briefly, cells were seeded into 96-well plates at a density of  $1 \times 10^4$  cells per well in the presence or absence of *p*-coumaric acid, ferulic acid, sinapic acid, doxorubicin, or  $\alpha$ -MSH. After two days of incubation, the mitochondrial enzyme activity, which is an indirect measure of the number of viable respiring cells, was determined using the MTT reagent. Finally, the absorbance was measured at 540 nm and the effect of *p*-coumaric acid, ferulic acid, sinapic acid, doxorubicin, or  $\alpha$ -MSH on cell viability was evaluated relative to a control without the test compounds.

### Cytotoxicity


The cytotoxicity was determined by the lactate dehydrogenase (LDH) release assay. The cytotoxic effect of *p*-coumaric acid, ferulic acid, sinapic acid, doxorubicin or  $\alpha$ -MSH was estimated by the measurement of LDH as the leakage of LDH is a well-known marker of the damage of cellular membrane. The cytotoxicity was expressed as the percentage of LDH released from the culture supernatant (LDH release in medium of  $\alpha$ -MSH, *p*-coumaric acid, ferulic acid, sinapic acid, or doxorubicin treatment/maximal LDH release  $\times 100$ ). Maximal LDH release was measured after lysis of the cells with 0.5% Triton X-100.

### Statistical analysis

All experiments were performed in triplicate. Treatment effects were analyzed using the Student's *t*-test;  $P < 0.05$  was considered to be statistically significant.

## RESULTS AND DISCUSSION

Previous studies show that melanogenesis, a marker of melanoma cell differentiation, is stimulated by methoxylated flavones, methoxylated coumarins, and hydroxylated flavones (7,12-17) which suggests that these compounds can be used as the improvement agents for acquired hypopigmentation disorders (21). Moreover, *p*-coumaric acid inhibits cellular melanogenesis induced by  $\alpha$ -MSH in B16/F10 melanoma cells (22) and  $\alpha$ -tocopheryl ferulate exerts depigmenting effects on human melanoma cells.  $\alpha$ -Tocopheryl ferulate is a compound of  $\alpha$ -tocopherol and ferulic acid connected by an ester bond (19). The effect of ferulic acid or sinapic acid on melanogenesis has not been previously studied (Fig. 1A). To investigate the effects of *p*-coumaric acid (CA), 3-methoxy-*p*-coumaric acid (FA), or 3,5-dimethoxy-*p*-coumaric acid (SA) on melanogenesis, B16/F10 melanoma cells were incubated with 500  $\mu$ g/mL of each compound



**Fig. 1.** Effects of *p*-coumaric acid derivatives on melanin production. (A) Chemical structure of *p*-coumaric acid, 3-methoxy-*p*-coumaric acid (ferulic acid), and 3,5-dimethoxy-*p*-coumaric acid (sinapic acid). (B) Relative intracellular melanin contents. # $P < 0.005$ , ## $P < 0.0005$ , ### $P < 0.00005$  compared to control without *p*-coumaric acid, ferulic acid, sinapic acid, and  $\alpha$ -MSH by Student's *t*-test. Con, negative control without *p*-coumaric acid, ferulic acid, sinapic acid, and  $\alpha$ -MSH; CA, 500  $\mu\text{g/mL}$  of *p*-coumaric acid; FA, 500  $\mu\text{g/mL}$  of ferulic acid; SA, 500  $\mu\text{g/mL}$  of sinapic acid; MSH, 50 nM of  $\alpha$ -MSH as a positive control. Bars represent means  $\pm$  SD of three independent experiments.


for 48 h. *p*-Coumaric acid showed an inhibitory effect on melanogenesis, but 3-methoxy-*p*-coumaric acid and  $\alpha$ -MSH increased melanin content 2- and 5-fold, respectively, and 3,5-dimethoxy-*p*-coumaric acid showed little effect on melanogenesis (Fig. 1B). These findings suggest that the 3-methoxy group added to *p*-coumaric acid (i.e. ferulic acid) is necessary for stimulating melanogenesis.

To confirm the safety and efficacy of ferulic acid for pharmaceutical use, intracellular melanin contents were determined by LDH release and the MTT assay with the doses previously indicated. After exposure of the cultured B16/F10 melanoma cells to ferulic acid or  $\alpha$ -MSH, cell viability decreased in a dose-dependent manner when treated with ferulic acid with maximum reduction of cell viability by 40% at 1,000  $\mu\text{g/mL}$ , compared to the control. However, ferulic acid did not affect the LDH release from the cells (Fig. 2A). Correlatively, treatment with ferulic acid resulted in a 2 to 3 fold elevation in the production of melanin. The most marked melanin synthesis occurred in the cells treated with 1,000  $\mu\text{g/mL}$  ferulic acid (Fig. 2B). These data show that ferulic acid exerts a cytostatic effect in B16/F10 melanoma cells rather than a cytotoxic effect. Interestingly, previous studies showed that nobiletin, a citrus hexamethoxyflavonoid, induces melanogenesis and cytostasis except for cytotoxicity in B16/F10 melanoma cells (2,7).


To demonstrate the cytotoxic effect of sinapic acid in B16/F10 melanoma cells, LDH release was determined

by intracellular melanin content and the MTT assay. Previous research has revealed that doxorubicin induces DNA fragmentation as a marker of apoptosis (2). Treatment with sinapic acid resulted in a 50~60% elevation in the release of lactate dehydrogenase (LDH) when treated with a concentration of 200  $\mu\text{g/mL}$  which is the highest LDH level detected. However, sinapic acid showed neither cytostasis nor increase of melanin synthesis in a dose-dependent manner (Fig. 3) which suggests that sinapic acid exerts cytotoxic effects, but not cytostatic effects. Furthermore, a subsequent study of sinapic acid will have to be performed to experiment on DNA fragmentation as a marker of apoptosis. With regards to methoxylated compounds, previous studies showed that sinapic acid has a neuroprotective potential in the 6-hydroxydopamine-induced hemi-parkinsonian rat (23) and tangeretin, a citrus pentamethoxyflavonoid, induces apoptosis in human gastric cancer cells (24).

In conclusion, these results indicate that *p*-coumaric acid inhibits melanogenesis, ferulic acid induces melanogenesis, and sinapic acid exerts cytotoxic effects in B16/F10 murine melanoma cells. This study suggests that the addition of methoxy groups to *p*-coumaric acid show the differential effects compared to original compounds. Contrary to *p*-coumaric acid as a hypopigmentation agent, ferulic acid, can be used as a chemopreventive agent.



**Fig. 2.** Cytostatic effects of a 3-methoxy-*p*-coumaric acid (ferulic acid). (A) Cytotoxicity using LDH assay and cell viability using MTT assay of ferulic acid. # $P < 0.001$ , \* $P < 0.05$ , \*\* $P < 0.005$ , \*\*\* $P < 0.00005$ , \*\*\*\* $P < 0.000005$ , \*\*\*\*\* $P < 0.0000005$  compared to control without ferulic acid and  $\alpha$ -MSH by Student's *t*-test. (B) Relative intracellular melanin contents # $P < 0.05$ , ## $P < 0.005$  compared to control without ferulic acid and  $\alpha$ -MSH by Student's *t*-test. Insert represents the raw data of intracellular melanin contents. Con, control without ferulic acid and  $\alpha$ -MSH; FA125, 125  $\mu\text{g/mL}$  of ferulic acid; FA250, 250  $\mu\text{g/mL}$  of ferulic acid; FA500, 500  $\mu\text{g/mL}$  of ferulic acid; FA1000, 1,000  $\mu\text{g/mL}$  of ferulic acid; MSH, 50 nM of  $\alpha$ -MSH as a positive control. Bars represent means $\pm$ SD of three independent experiments.



**Fig. 3.** Cytotoxic effects of a 3,5-dimethoxy-*p*-coumaric acid (sinapic acid). (A) Relative intracellular melanin contents. # $P < 0.05$ , ## $P < 0.005$ , ### $P < 0.0005$  compared to control without sinapic acid and  $\alpha$ -MSH by Student's *t*-test. (B) Cytotoxicity using LDH assay and cell viability using MTT assay of sinapic acid. # $P < 0.01$ , ## $P < 0.005$ , ### $P < 0.0001$ , \* $P < 0.05$ , \*\* $P < 0.005$ , \*\*\* $P < 0.0005$  compared to control without sinapic acid and  $\alpha$ -MSH by Student's *t*-test. Con, control without sinapic acid and  $\alpha$ -MSH; SA50, 50  $\mu\text{g/mL}$  of sinapic acid; SA100, 100  $\mu\text{g/mL}$  of sinapic acid; SA200, 200  $\mu\text{g/mL}$  of sinapic acid; Doxo, 1  $\mu\text{M}$  of doxorubicin as an apoptosis inducer; MSH, 100 nM of  $\alpha$ -MSH as a positive control. Bars represent means $\pm$ SD of three independent experiments.

## ACKNOWLEDGEMENTS

This research was supported by the 2014 scientific promotion program funded by Jeju National University.

## AUTHOR DISCLOSURE STATEMENT

The authors declare no conflict of interest.

## REFERENCES

- Chin L, Garraway LA, Fisher DE. 2006. Malignant melanoma: Genetics and therapeutics in the genomic era. *Genes Dev* 20: 2149-2182.
- Yoon HS, Kim IJ. 2011. Nobiletin induces differentiation of murine B16/F10 melanoma cells. *J Korean Soc Appl Biol Chem* 54: 353-361.
- Fisher PB, Grant S. 1985. Effects of interferon on differentiation of normal and tumor cells. *Pharmacol Ther* 27: 143-166.
- Jiménez M, Kameyama K, Maloy WL, Tomita Y, Hearing VJ. 1988. Mammalian tyrosinase: Biosynthesis, processing, and modulation by melanocyte-stimulating hormone. *Proc Natl*

- Acad Sci USA* 85: 3830-3834.
5. Videria IFS, Moura DFL, Magina S. 2013. Mechanisms regulating melanogenesis. *An Bras Dermatol* 88: 76-83.
  6. Walle T. 2007. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? *Semin Cancer Biol* 17: 354-362.
  7. Yoon HS, Lee SR, Ko HC, Choi SY, Park JG, Kim JK, Kim SJ. 2007. Involvement of extracellular signal-regulated kinase in nobiletin-induced melanogenesis in murine B16/F10 melanoma cells. *Biosci Biotechnol Biochem* 71: 1781-1784.
  8. Young SW, Dickens M, Tavaré JM. 1994. Differentiation of PC12 cells in response to cAMP analogue is accompanied by sustained activation of mitogen-activated protein kinase. Comparison with the effects of insulin, growth factors and phorbol esters. *FEBS Lett* 338: 212-216.
  9. Lam IK, Alex D, Wang YH, Liu P, Liu AL, Du GH, Lee SMY. 2012. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: Identifying sinensetin as a novel antiangiogenesis agent. *Mol Nutr Food Res* 56: 945-956.
  10. Laavola M, Nieminen R, Yam MF, Sadikun A, Asmawi MZ, Basir R, Welling J, Vapaatalo H, Korhonen R, Moilanen E. 2012. Flavonoids eupatorin and sinensetin present in *Orthosiphon staminus* leaves inhibit inflammatory gene expression and STAT1 activation. *Planta Med* 78: 779-786.
  11. Van Slambrouck S, Parmar VS, Sharma SK, De Bondt B, Foré F, Coopman P, Vanhoecke BW, Boterberg T, Depypere HT, Lecleroq G, Bracke ME. 2005. Tangeretin inhibits extracellular signal-regulated kinase (ERK) phosphorylation. *FEBS Lett* 579: 1665-1669.
  12. Kumagai A, Horike N, Satoh Y, Uebi T, Sasaki T, Itoh Y, Hirata Y, Uchio-Yamada K, Kitagawa K, Uesato S, Kawahara H, Takemori H, Nagaoka Y. 2011. A potent inhibitor of SIK2, 3, 3', 7-trihydroxy-4'-methoxyflavon (4'-O-methylfisetin), promotes melanogenesis in B16F10 melanoma cells. *PLOS ONE* 6: e26148.
  13. Yang JY, Koo JH, Song YG, Kwon KB, Lee JH, Sohn HS, Park BH, Jhee EC, Park JW. 2006. Stimulation of melanogenesis by scoparone in B16 melanoma cells. *Acta Pharmacol Sin* 27: 1467-1473.
  14. Alesiani D, Cicconi R, Mattei M, Bei R, Canini A. 2009. Inhibition of MEK1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells. *Int J Oncol* 34: 1727-1735.
  15. Nagata H, Takekoshi S, Takeyama R, Homma T, Yoshiyuki Osamura R. 2004. Quercetin enhances melanogenesis by increasing activity and synthesis of tyrosinase in normal human melanocytes. *Pigment Cell Res* 17: 66-73.
  16. Ohguchi K, Akao Y, Nozawa Y. 2006. Stimulation of melanogenesis by the citrus flavonoid naringenin in mouse B16 melanoma cells. *Biosci Biotechnol Biochem* 70: 1499-1501.
  17. Chen X, Zhang B, Yuan X, Yang F, Lin J, Zhan H, Lin L, Wang Y, Wang Z, Zheng Q. 2012. Isoliquiritigenin-induced differentiation in mouse melanoma B16F0 cell line. *Oxid Med Cell Longev* 2012: 534934.
  18. Lee JS, Jung KS, Kim YS, Park D. 2007. Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling. *Life Sci* 81: 249-254.
  19. Funasaka Y, Chakraborty AK, Komoto M, Ohashi A, Ichihashi M. 1999. The depigmenting effect of  $\alpha$ -tocopheryl ferulate on human melanoma cells. *Br J Dermatol* 141: 20-29.
  20. Lee J, Jung E, Lee J, Huh S, Boo YC, Hyun CG, Kim YS, Park D. 2007. Mechanisms of melanogenesis inhibition by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. *Br J Dermatol* 157: 242-248.
  21. Lee JS, Kim YS, Park DH. 2007. Rosemarinic acid induces melanogenesis through protein kinase A activation signaling. *Biochem Pharmacol* 74: 960-968.
  22. An SM, Lee SJ, Choi SW, Moon SW, Boo YC. 2008. *p*-Coumaric acid, a constituent of *Sasa quelpaertensis* Nakai, inhibits cellular melanogenesis stimulated by  $\alpha$ -melanocyte stimulating hormone. *Br J Dermatol* 159: 292-299.
  23. Zare K, Eidi A, Roghani M, Rohani AH. 2014. The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat. *Metab Brain Dis* 30: 201-213.
  24. Dong Y, Cao A, Shi J, Yin P, Wang L, Ji G, Xie J, Wu D. 2014. Tangeretin, a citrus polymethoxyflavonoid, induces apoptosis of human gastric cancer AGS cells through extrinsic and intrinsic signaling pathways. *Oncol Rep* 31: 1788-1794.